Here we thoroughly characterize these ex vivo differentiated CRC-specific MDSC, demonstrate that their functions could be counteracted by arg-1 and iNOS inhibitors and that these treatments possess therapeutic activities in vivo. Here, NOS2 is linked to colorectal carcinoma.